# Pharmacokinetic, Safety and Immunogenicity Study of CMAB809 and Herceptin in Healthy Volunteers

> **NCT04049409** · PHASE1 · COMPLETED · sponsor: **Taizhou Mabtech Pharmaceutical Co.,Ltd** · enrollment: 72 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** CMAB809
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT04049409
- **Lead sponsor:** Taizhou Mabtech Pharmaceutical Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-17
- **Primary completion:** 2019-11-20
- **Final completion:** 2019-11-20
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2020-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04049409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04049409, "Pharmacokinetic, Safety and Immunogenicity Study of CMAB809 and Herceptin in Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04049409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*